The NIH grant will support the continued development of the CapScan device, including clinical trials to evaluate its efficacy and usability. The goal of the project is to demonstrate that the CapScan device is a reliable tool that sheds new light on the activities of the gut microbes and their associated metabolites in health and disease.
“We are thrilled to receive this grant from the NIH, which will allow us, together with our collaborators at Stanford University and the University of California Davis, to continue developing the CapScan device and demonstrate its potential to improve our understanding of the gut microbiome,” said Dari Shalon PhD, Founder and CEO of Envivo Bio. “CapScan is a novel device that explores the under-explored world of small intestine physiology. We believe that CapScan has the potential to provide a more accurate picture of most gut activities as compared to current methods.”
The CapScan device has the potential to revolutionize the way scientists and clinicians measure the microbial and biochemical activities in the small intestines. With the support of the NIH grant, Envivo Bio is excited to continue developing this innovative technology and bring it to market in the near future.
